NeuroPace (NPCE)
Provides implanted brain-responsive stimulation and data tools for adults with drug-resistant focal epilepsy.
$14.71
After hours−0.01 (−0.07%)
At close$14.72(+1.24%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16 | 18 | 18 | 19 | 21 | 21 | 23 | 24 | 27 | 27 | 22 | 23 |
| Cost of revenue | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 5 | 6 | 6 | 4 | 4 |
| Gross profit | 12 | 14 | 13 | 14 | 15 | 16 | 17 | 18 | 21 | 21 | 18 | 19 |
| 18 | 19 | 21 | 20 | 20 | 20 | 22 | 25 | 24 | 22 | 24 | 24 | |
| Research & development | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 7 |
| 13 | 13 | 15 | 14 | 14 | 14 | 15 | 18 | 17 | 15 | 16 | 17 | |
| Selling & marketing | 0 | 0 | 0 | 10 | 0 | 0 | 11 | 12 | 13 | 11 | 12 | 12 |
| General & administrative | 0 | 0 | 0 | 5 | 0 | 0 | 4 | 6 | 5 | 4 | 5 | 5 |
| Operating income | −6 | −5 | −8 | −6 | −4 | −4 | −5 | −7 | −3 | −2 | −6 | −5 |
| −1 | −1 | −1 | −1 | −1 | −2 | −1 | −2 | −1 | −1 | −1 | −1 | |
| Interest income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest expense | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other non-operating income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 0 | 0 | −1 | 0 | 0 |
| Income before tax | −7 | −6 | −9 | −8 | −5 | −5 | −7 | −9 | −3 | −3 | −7 | −6 |
| Net income from continuing operations | −7 | −6 | −9 | −8 | −5 | −5 | −7 | −9 | −3 | −3 | −7 | −6 |
| Net income | −7 | −6 | −9 | −8 | −5 | −5 | −7 | −9 | −3 | −3 | −7 | −6 |
| EPS, basic | −$0.28 | −$0.24 | −$0.32 | −$0.26 | −$0.19 | −$0.18 | −$0.21 | −$0.26 | −$0.11 | −$0.08 | −$0.20 | −$0.18 |
| EPS, diluted | −$0.28 | −$0.24 | −$0.32 | −$0.26 | −$0.19 | −$0.18 | −$0.21 | −$0.26 | −$0.11 | −$0.08 | −$0.20 | −$0.18 |
| Weighted average shares, basic | 26 | 26 | 28 | 29 | 29 | 30 | 31 | 33 | 33 | 33 | 34 | 34 |
| Weighted average shares, diluted | 26 | 26 | 28 | 29 | 29 | 30 | 31 | 33 | 33 | 33 | 34 | 34 |
| EBITDA | −5 | −4 | −6 | −5 | −3 | −3 | −4 | −6 | −2 | −1 | −5 | −5 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| EBIT | −5 | −4 | −7 | −5 | −3 | −3 | −4 | −7 | −3 | −1 | −5 | −5 |